Pierre Fabre letter on Navelbine oral dosing ruled promotional: missing PI/AE statement and misleading efficacy/monitoring messaging

📊

Key facts

⌄

Case	AUTH/2727/8/14
Complainant	Pharmacist
Company	Pierre Fabre
Medicine	Navelbine (vinorelbine) oral
Material	Letter to oncology pharmacists headed “Under-dosing of Navelbine Oral” with bar chart
Key disputed positioning	Company said “safety letter”; Panel ruled it was promotional
Complaint received	16 August 2014
Case completed	30 October 2014
Applicable Code year	2014
Breach clauses	3.2, 4.1, 4.10, 7.2, 7.4
No breach clauses	4.3, 7.8, 12.1
Sanctions	Undertaking received; Additional sanctions: Not stated
Appeal	No appeal
Panel concerns noted	Market research did not clearly substantiate “under-dosing”; monitoring requirements not made clear; “recommended dose” emphasis could mislead given patient-specific appropriateness

Reviewed by Dr Anzal Qurbain (FFPM) — ABPI Final Signatory

🤖

Got a question about this case?

Ask one of our 13 specialist ABPI advisors — instant answers, 24/7.

Ask AskAnzal AI

🎬 Expert Video Walkthrough

🎬

Video walkthrough — coming for members

Subscribe now and get expert video analysis for every case as we publish them.

Subscribe — from £299/yr

📋

⌄

A pharmacist complained about a letter sent by Pierre Fabre to oncology pharmacists about Navelbine (vinorelbine) oral dosing.
The letter (dated 5 August) was headed “Under-dosing of Navelbine Oral” and stated the only recommended single-agent dose in advanced breast cancer was 80mg/m² weekly (following three doses at 60mg/m²).
It encouraged recipients to check local protocols to ensure Navelbine oral was used at the “appropriate dose” and included a bar chart comparing dose delivered per cycle.
Pierre Fabre argued it was a non-promotional safety letter from the medical department, prompted by market research suggesting under-dosing and requests from HCPs.
The complainant alleged (among other points) that the letter lacked prescribing information and AE reporting wording, used an unqualified indication (“Advanced Breast Cancer”), did not reflect SPC exclusions/monitoring requirements (blood counts), and made an efficacy/survival implication without adequate substantiation.

⚖️

⌄

The Panel ruled the letter was promotional (it did not meet any exemption; not MHRA-requested; not triggered by safety reporting/analysis; brand referenced multiple times).
Breaches were ruled for missing prescribing information and AE reporting statement, an indication not fairly reflecting the licence, and misleading/unsubstantiated claims and monitoring information.
No breach was ruled for non-proprietary name size, the bar chart on the narrow grounds alleged, and alleged disguised promotion.
No appeal.

🔒

Members get the complete breakdown — Clauses, Sanction, Signatory Lens, Audit checklist, and 3 Key Questions.

Best value

£249/year

Annual — save £99

£29/mo

Monthly

Join Now — Instant Access